11 completed, 2 unknown. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 11, Unknown 2 |
| Phase 2 | 1 | Completed 1 |
Follow Acute Pyelonephritis: new trials by email Literature Review of Acute Pyelonephritis trials Research Report on Acute Pyelonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) WCK 4282 (FEP-TAZ) 4 g, Meropenem, ciprofloxacin 500 mg Optional Oral Switch - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Unknown | Wockhardt | 1004 | 2024-01-01 | 2023-07-17 |
| A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion - Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Spero Therapeutics | 1690 | 2023-12-21 | 2026-03-10 |
| P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, BAT - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Meiji Seika Pharma Co., Ltd. | 126 | 2023-09-22 | 2026-04-13 |
| Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, imipenem/cilastatin - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Meiji Seika Pharma Co., Ltd. | 614 | 2023-05-23 | 2025-12-24 |
| Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Cefepime-zidebactam (FEP-ZID), Meropenem - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Wockhardt | 530 | 2022-08-28 | 2026-05-22 |
| Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children Dexamethasone Oral, Placebo - Urinary Tract Infections in Children, Dexamethasone | Phase 3 | Unknown | Hamad Medical Corporation | 120 | 2021-03-03 | 2023-07-25 |
| Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections Cefepime/VNRX-5133 (taniborbactam), Meropenem - Urinary Tract Infections, Acute Pyelonephritis | Phase 3 | Completed | Venatorx Pharmaceuticals, Inc. | 661 | 2019-08-07 | 2025-06-06 |
| Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) TBPM-PI-HBr, Ertapenem, Dummy Infusion - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Spero Therapeutics | 1372 | 2019-06-03 | 2022-07-25 |
| Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections ZTI-01, Piperacillin-tazobactam - Urinary Tract Infection Symptomatic, Acute Pyelonephritis | Phase 2 / Phase 3 | Completed | Nabriva Therapeutics AG | 465 | 2016-04-01 | 2019-03-07 |
| A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) plazomicin, meropenem, levofloxacin (oral) - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Achaogen, Inc. | 609 | 2016-01-11 | 2018-08-23 |
| Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin - Urinary Tract Infection Complicated, Acute Pyelonephritis | Phase 3 | Completed | Melinta Therapeutics, Inc. | 550 | 2014-11-20 | 2018-06-11 |
| Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Vabomere, Best Available Therapy - Urinary Tract Infection Complicated, Acute Pyelonephritis | Phase 3 | Completed | Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | 77 | 2014-07-01 | 2019-03-04 |
| CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria CSE-1034 (Ceftriaxone + Sulbactam + EDTA), Meropenem - Urinary Tract Infection Complicated, Acute Pyelonephritis | Phase 3 | Completed | Venus Remedies Limited | 230 | 2014-01-11 | 2019-08-29 |
Bacterial Infections (3) · Urinary Tract Infections (3) · Bacteremia (1) · Glomerulonephritis (1) · Infections (1) · Intraabdominal Infections (1) · Kidney Failure, Chronic (1) · Pyelonephritis (1)
Bacterial Infections and Mycoses (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Infections (4) · Male Urogenital Diseases (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Kidney Diseases (2) · Nephritis (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bacterial Infections (1) · Chronic Disease (1) · Disease Attributes (1) · Inflammation (1)
Meropenem (6) · Cilastatin, Imipenem Drug Combination (2) · Levofloxacin (2) · Piperacillin, Tazobactam Drug Combination (2) · beta-Lactamase Inhibitors (2) · meropenem and vaborbactam (2) · nacubactam (2) · tebipenem (2) · vaborbactam (2) · Adrenal Cortex Hormones (1) · Anti-Bacterial Agents (1) · Ceftriaxone (1) · Ciprofloxacin (1) · Dexamethasone (1) · Edetic Acid (1)
Meiji Seika Pharma Co., Ltd. (2) · Spero Therapeutics (2) · Wockhardt (2) · Achaogen, Inc. (1) · Hamad Medical Corporation (1) · Melinta Therapeutics, Inc. (1) · Nabriva Therapeutics AG (1) · Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) (1) · Venatorx Pharmaceuticals, Inc. (1) · Venus Remedies Limited (1)
Bulgaria (7) · Slovakia (7) · United States (7) · Latvia (6) · Czechia (5) · Estonia (5) · Georgia (5) · Greece (5) · Hungary (5) · Poland (5) · Romania (5) · Brazil (4) · China (4) · Croatia (4) · Ukraine (4)
Karen Fusaro (2) · Keith Kaye (2) · A.K. Deb (1) · David Hong, MD (1) · David Melnick, MD (1) · Deepak Dewan (1) · Dharamraj Maurya (1) · Evelyn J Ellis-Grosse, PhD (1) · Kim Mammen (1) · Lynn E Connolly, MD, PhD (1) · Madhav Prabhu (1) · Mahmoud Alhandi Omar Helal (1) · Manishkumar D Shah, PhD (1) · Manjunath M (1) · Mohd. Shameem (1)
PMID 29486041, PMID 30270406, PMID 30786187, PMID 30861061, PMID 31433059, PMID 33332545, PMID 33565042, PMID 35388666, PMID 38354140, PMID 38780262, PMID 40827922, PMID 42134354
2015 (2), 2018 (2), 2023 (1)